TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ANI Pharmaceuticals ( (ANIP) ) has issued an update.
On November 24, 2025, Patrick D. Walsh announced he would not seek re-election as a director at ANI Pharmaceuticals‘ 2026 Annual Meeting and stepped down as Chairman of the Board. Thomas J. Haughey was elected as the new Chairman, while Jeanne A. Thoma replaced him as Chair of the Audit and Finance Committee. This leadership transition is expected to support ANI’s focus on expanding its Rare Disease business and delivering growth for shareholders.
The most recent analyst rating on (ANIP) stock is a Hold with a $93.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
Spark’s Take on ANIP Stock
According to Spark, TipRanks’ AI Analyst, ANIP is a Neutral.
ANI Pharmaceuticals’ strong earnings call performance and revenue growth are significant positives, but challenges in profitability and high valuation metrics weigh on the overall score. Technical indicators suggest bearish momentum, adding caution to the outlook.
To see Spark’s full report on ANIP stock, click here.
More about ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics. The company emphasizes sustainable growth through its Rare Disease business, which markets products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with its Generics and Brands businesses.
Average Trading Volume: 381,193
Technical Sentiment Signal: Buy
Current Market Cap: $1.91B
For an in-depth examination of ANIP stock, go to TipRanks’ Overview page.